This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031–1037
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Fernandez Reese S, Ford JM, Capdeville R, Talpaz M . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 2001 344: 1038–1042
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B on behalf of the International STI571 CML Study Group. Imatinib mesylate (Gleevec) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in chronic phase: results of a phase II study N Engl J Med 2002 346: 645–652
Ottmann OG, Sawyers C, Druker B, Goldman J, O'Brien SG, Reiffers J, Silver RT, Tura S, Fischer T, Niederwieser D, Schiffer C, Baccarani M, Gratwohl A, Hochhaus A, Reese SF, Capdeville R . Phase II study of STI571 in adult patients with Philadelphia chromosome (Ph) positive acute leukaemias Hematol J 2001 2 (Suppl. 1): 93
Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller C, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MWN, Fischer T, O'Brien SG, Stone R, Gambacorti-Passerini C, Russell N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ . Glivec (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study Blood 2002 99: 3530–3539
Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Niederwieser D, O'Brien SG, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL . Imatinib induces hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study Blood 2002 99: 1928–1937
Druker BJ for the IRIS (International Randomized IFN vs STI571) Study Group. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study Proc Am Soc Clin Oncol 2002 21: 1a
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 2001 293: 876–880
von Bubnoff N, Schneller F, Peschel C, Duyster J . BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study Lancet 2002 359: 487–491
Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP . Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation Blood 2002 99: 1860–1862
Hochhaus A, Kreil S, Corbin A, La Rosée P, Lahaye T, Berger U, Cross NCP, Linkesch W, Druker BJ, Hehlmann R . Roots of clinical resistance to STI-571 cancer therapy Science 2001 293: 2163a
Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX . Roots of clinical resistance to STI-571 cancer therapy Science 2001 293: 2163a
Tabrizi R, Mahon FX, Cony Makhoul P, Lagarde V, Lacombe F, Berthaud P, Melo JV, Reiffers J, Belloc F . Resistance to daunorubicine-induced apoptosis is not completely reversed in CML blast cells by STI571 Leukemia 2002 16: 1154–1160
Cross NCP, Reiter A . Tyrosine kinase fusion genes in chronic myeloproliferative diseases Leukemia 2002 16: 1207–1212
La Rosée P, O'Dwyer ME, Druker BJ . Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (GleevecTM/GlivecΛ) in chronic myelogenous leukemia: a translational perspective Leukemia 2002 16: 1213–1219
Fischer T, Reifenrath C, Hess GR, Corsetti MT, Kreil S, Beck J, Meinhardt P, Beltrami G, Schuch B, Gschaidmeier H, Hehlmann R, Hochhaus A, Carella A, Huber C . Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSC-T) Leukemia 2002 16: 1220–1228
Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K . Clonal Ph-negative hematopoiesis observed after therapy of CML with imatinib mesylate is frequently characterized by trisomy 8 Leukemia 2002 16: 1390–1394
Selle B, Bär C, Hecker S, Schmidt-Rohr U, Viehmann S, Debatin KM, Reinhardt D . ABL specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia-chromosome-positive acute mixed lineage leukemia (AMLL) Leukemia 2002 16: 1394–1395
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hochhaus, A., McCubrey, J. & Muller-Bérat Killmann, N. Spotlight Imatinib: a model for signal transduction inhibitors. Leukemia 16, 1205–1206 (2002). https://doi.org/10.1038/sj.leu.2402575
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402575
This article is cited by
-
Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib
Leukemia (2003)
-
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
Leukemia (2003)